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Aims: Saxagliptin is a dipeptidyl peptidase-4 inhibitor that was approved in Japan for the
treatment of type 2 diabetes in 2013. We examined its efficacy and safety in Japanese
hemodialysis patients with diabetic nephropathy.
Methods: In this prospective, open-label, parallel-group study, Japanese hemodialysis
patients were randomized to receive either oral saxagliptin (2.5 mg/day) or usual care (con-
trol group) for 24 weeks. Before randomization, patients received fixed doses of conven-
tional antidiabetic drugs (oral drugs and/or insulin) for 8 weeks; these drugs were
continued during the study. Endpoints included changes in glycated albumin (GA), hemo-
globin A1c (HbA1c), postprandial plasma glucose (PPG), and adverse events.
Results: Both groups included 41 patients. Mean GA, HbA1c, and PPG decreased signifi-
cantly in the saxagliptin group (3.4%, 0.6% [7 mmol/mol], and 38.3 mg/dL, respec-
tively; all P < 0.0001) but not in the control group (0%, 0.1% [1 mmol/mol], and
3.7 mg/dL, respectively) (P < 0.0001, P < 0.001, and P < 0.0001, respectively). In
saxagliptin-treated patients, the reduction in GAwas significantly greater when saxagliptin
was administered as monotherapy than in combination therapy (4.2% vs. 3.0%,
P = 0.012) despite similar baseline values (24.5% vs. 23.3%). Reductions in GA, HbA1c, and
PPG were greater in patients whose baseline values exceeded the median (23.8% for GA,, 2015).
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saxagliptin.
Conclusions: Saxagliptin (2.5 mg/day) was effective and well tolerated when used as
monotherapy or combined with other antidiabetic drugs in Japanese hemodialysis patients
with type 2 diabetes.
Clinical Trial Registration number: UMIN000018445.
 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction 2. Materials and methodsIn patients with type 2 diabetes on hemodialysis, the accumu-
lation of antidiabetic drugs or their metabolites between
hemodialysis sessions and their rapid clearance during
hemodialysis make it difficult to predict the pharmacological
effects of these drugs, hampering efforts to achieve and
maintain glycemic control. For these reasons, sulfonylureas
are unsuitable owing to the risk of prolonged hypoglycemia,
while metformin is contraindicated in patients with moder-
ate to advanced chronic kidney disease, including hemodial-
ysis [1]. Patients on hemodialysis are also at high risk of
hemodialysis-induced hypoglycemia, and low and high glu-
cose levels are associated with poor outcomes, including a
high risk of death [2].
Insulin is considered to be the most effective treatment for
type 2 diabetes in hemodialysis patients, but the risk of hypo-
glycemia remains a significant concern necessitating careful
dosing and monitoring of blood glucose concentrations [1].
a-Glucosidase inhibitors and glinides were reportedly effec-
tive in improving glycemic control and had low risks of hypo-
glycemia in hemodialysis patients [3,4]. However, these drugs
are not available in all countries, and the original National
Kidney Foundation Kidney Disease Outcomes Quality Initia-
tive (KDOQI) guidelines recommended that a-glucosidase
inhibitors should be avoided in patients with advanced stage
chronic kidney disease (CKD) and on dialysis [5]. Several novel
classes of antidiabetic drugs have been introduced since the
original KDOQI guidelines, including dipeptidyl peptidase-4
(DPP-4) inhibitors, and these classes of drugs have been incor-
porated into the updated guidelines [6].
In Japanese hemodialysis patients, prior studies have
shown favorable efficacy and safety profiles of the DPP-4 inhi-
bitors alogliptin, teneligliptin, and vildagliptin [7–9]. Saxaglip-
tin is a newer member of the DPP-4 class that was approved in
Japan for the treatment of type 2 diabetes in 2013. Accordingly,
studies are needed to verify the efficacy and safety of saxaglip-
tin in Japanese hemodialysis patients with type 2 diabetes.
Therefore, we performed a randomized controlled study to
verify the efficacy and safety of saxagliptin in these patients.
For the purpose of this study, the major glycemic endpoint
was the change in glycated albumin (GA), rather than the
change in hemoglobin A1c (HbA1c), because the former is a
better marker for glycemic variability in hemodialysis
patients and is less likely to be affected by factors such as ery-
thropoiesis stimulating agent (ESA) dose, anemia, and iron
administration [10–12].2.1. Ethics
The study protocol was approved by the Ethics Committee of
Keiai Hospital, and all patients provided written informed
consent (Clinical Trial Registration number: UMIN000018445;
ethics board approval number: RK-20140701-02). The study
protocol was designed in accordance with the Declaration of
Helsinki.2.2. Subjects
Enrollment criteria for the study were as follows: (1)
ageP 20 years and 680 years, (2) hemodialysis duration
>6 months at enrollment, (3) type 2 diabetes mellitus, and
(4) poor glycemic control which was defined as a glycated
albumin (GA) level exceeding 20.0% after 8 consecutive weeks
of daily administration of conventional therapy (dietary ther-
apy alone, oral antidiabetic agents and/or insulin). Exclusion
criteria were as follows: (1) age < 20 years or >80 years; (2) a
history of severe heart failure, angina, myocardial infarction,
or stroke within the past 6 months; (3) the presence of infec-
tious disease, liver dysfunction, thyroid disease, malignant
tumors, or treatment with steroids or immunosuppressants;
(4) current hospitalization; and (5) treatment with any DPP-4
inhibitor within the past 6 months.2.3. Study design and treatments
This study was designed similarly to our prior studies of alo-
gliptin and vildagliptin [7,8]. This prospective, open-label,
parallel-group, multi-center study was conducted between
June 2014 and October 2015, and eligible patients were ran-
domized to receive oral saxagliptin (2.5 mg/day) or usual care
for 24 weeks. Before randomization, patients received fixed
doses of conventional antidiabetic drugs (oral hypoglycemic
agents and/or insulin) for 8 weeks, and these drugs were con-
tinued during the 24-week treatment period. If the GA value
remainedP20.0% after 12 weeks of treatment in either group,
the dose(s) of other antidiabetic drugs could be increased. If
the investigator believed that saxagliptin presented a safety
problem, its administration was to be interrupted. Patients
continued their regular medications, such as anti-
hypertensive drugs, ESAs, phosphate binders and lipid-
lowering agents, during the study period.
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pendent investigator with no previous knowledge of the sub-
jects. Dynamic balancing randomization was applied, taking
into account age, sex, hemodialysis duration, and hemoglo-
bin concentration to minimize potential differences in base-
line characteristics between the groups. The details of the
assignment were then given to seven independent investiga-
tors, who provided patient care at the four hemodialysis cen-
ters involved in this study.
2.4. Hemodialysis
In all patients, hemodialysis was performed for 4 h at a blood
flow rate of 200 mL/min and a dialysate flow rate of 500 mL/
min. Hemodialysis was performed using dialyzers containing
high-flux membranes. The surface area of the dialyzer mem-
brane was selected according to the patient’s body weight.
The glucose concentration of the dialysate was 100 mg/dL.
Heparin was administered at a dose of 2600–5000 units per
4-h hemodialysis session for anticoagulation. The volume of
ultrafiltration was maintained on the basis of clinical dry
weight during each session.
Blood samples were obtained before the start of each
hemodialysis session. All patients received recombinant
human erythropoietin (epoetin alpha). The erythropoietin
responsiveness index (ERI) was defined as the mean weekly
ESA dose divided by the clinical dry weight and mean blood
hemoglobin [i.e., ERI = weekly ESA dose (units)/dry weight
(kg)/hemoglobin (g/dL)] to normalize the ESA dose according
to the severity of anemia [13].
2.5. Study evaluations and endpoints
The primary efficacy endpoint was the change in GA. Sec-
ondary endpoints included changes in vital signs and labo-
ratory/biochemical tests during the study, and safety. GA
and HbA1c levels were measured every month as indices
of glycemic control. Postprandial plasma glucose (PPG) levels
were measured three times per week before each hemodial-
ysis session, and results are expressed as the mean PPG val-
ues of 12 measurements per month. Vital signs, including
body weight, interdialytic weight gain, body mass index
(BMI), cardiothoracic ratio on chest X-ray, and predialysis
systolic and diastolic blood pressures were recorded every
month. Hemoglobin, aspartate aminotransferase, alanine
aminotransferase, lactate dehydrogenase, alkaline phos-
phatase, c-glutamyl transpeptidase, total cholesterol, high-
density lipoprotein, triglyceride, total protein, and albumin
concentrations were measured by routine clinical chemistry
procedures using commercially available assay kits. PPG,
HbA1c, and GA were measured using the same assay kits
in all four centers. GA was measured by an enzymatic
method using the Lucica GA-L Kit (Asahi Kasei Pharma
Co., Tokyo, Japan).
All variables were assessed every month during the 8-
week pre-treatment observation period and the 24-week
treatment period. Efficacy variables were analyzed in all sub-
jects, and in patients divided into several subgroups by age,BMI, and treatment regimen (monotherapy vs. combination
with oral antidiabetic drugs and/or insulin).
Subjects could be withdrawn in the event of allergy/intol-
erance to the drug, if either the serum transaminase concen-
tration or creatine kinase concentration increased to more
than 2 the upper limit of normal, or following an event that,
in the investigator’s opinion, might have posed a risk to the
patient or confounded the results of the study.
At each visit, subjects were questioned with regard to
study compliance (diet and medications), concomitant medi-
cations, and adverse events (AEs). Safety assessments were
performed throughout the study. AEs were graded by inten-
sity: mild, moderate, or severe. Serious adverse events were
defined as medical events that resulted in death, hospitaliza-
tion, or significant disability or incapacity.
2.6. Statistical analyses
Data are expressed as the mean ± standard deviation or med-
ian (interquartile range) as appropriate. Continuous variables
were compared using the Student’s t-test or the Mann–Whit-
ney U test, and categorical variables were compared using the
v2 test or Fisher’s exact test. Statistical significance was set at
P < 0.05. All analyses were performed using JMP software ver-
sion 12 (SAS Institute Ltd., Cary, NC, USA).
The sample size was determined based on 80% power,
assuming an effect size of a 4% difference in the change in
GA from baseline between the two groups and a standard
deviation of 3.0%, based on the results of a previous trial [8].
This yielded a two-sided significance level of 0.05, and an esti-
mated number of evaluable patients of 26 (13 per group).
Allowing for a dropout rate of 10% after randomization, a
sample size of 30 randomized subjects (15 per group) was nec-
essary for this study. To collect additional data on the efficacy
and safety of saxagliptin, we chose to enroll approximately 40
patients per group.
3. Results
3.1. Subjects
A total of 534 patients were initially screened and 84 patients
were randomly assigned to the saxagliptin group (n = 42) or
the control group (n = 42). Details of patient disposition are
shown in Supplementary Fig. 1. All of the patients had anuria
and all had poor glycemic control. The primary renal diagno-
sis was diabetic nephropathy caused by type 2 diabetes melli-
tus. One patient in the saxagliptin group was admitted to
hospital owing to pneumonia, and one patient in the control
group was prescribed a DPP-4 inhibitor owing to severe hyper-
glycemia. Both of these patients were excluded from the final
analysis, so 41 patients were analyzed in each group. Data
were available for all 82 patients at all time-points. As shown
in Table 1, there were no significant differences in the base-
line demographic, hemodynamic, or anthropometric vari-
ables; dialysis mode; type of vascular access; cardiovascular
comorbidities; or medications between the two groups. The
saxagliptin dose was not changed in any patient and none
Table 1 – Patient characteristics at baseline.
Variable Saxagliptin group Control group P value
N 41 41
Males 27 (65.9) 28 (68.3) 0.816
Age (years) 66.9 ± 9.4 66.3 ± 9.4 0.282
Hemodialysis duration (m) 50.9 ± 33.7 50.2 ± 33.0 0.929
Body mass index (kg/m2) 22.8 ± 3.7 22.9 ± 3.7 0.837
Postprandial plasma glucose (mg/dL) 186 ± 35 185 ± 47 0.832
Glycated albumin (%) 23.7 ± 2.9 23.6 ± 2.7 0.597
Hemoglobin A1c (% [mmol/mol]) 6.5 ± 0.8 6.5 ± 0.7 0.929
(48 ± 8.8) (48 ± 7.7)
Cardiovascular comorbidities
Ischemic heart disease 7 (17.1) 6 (14.6) 0.765
Cerebral vascular events 2 (4.9) 1 (2.4) 0.562
Peripheral artery disease 3 (7.3) 2 (4.9) 0.649
Dialysis mode 0.697
Hemodialysis 38 (92.7) 37 (90.2)
Hemodiafiltration 3 (7.3) 4 (9.8)
Type of vascular access 0.727
Arteriovenous fistula 36 (87.8) 35 (85.4)
Arteriovenous graft 5 (12.2) 6 (14.6)
Catheter 0 0
Antidiabetic therapy
Oral antidiabetic agents 20 (48.8) 21 (51.2) 0.827
Insulin therapy 5 (12.2) 6 (14.6) 0.749
Oral antidiabetic agents + insulin 4 (9.7) 3 (7.4) 0.697
Diet alone 12 (29.3) 11 (26.8) 0.808
Use of renin-angiotensin system inhibitors 34 (82.9) 33 (80.5) 0.778
Use of statins 18 (43.9) 19 (46.3) 0.827
Values are shown as the n (%) or mean ± standard deviation.
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abetic drug. One patient in the control group was prescribed a
DPP-4 inhibitor during the study and was withdrawn from the
study. The dose of repaglinide was increased in three patients
in the control group because of poor glycemic control. Dura-
tion of diabetes was also significantly associated with
hemodialysis duration (Supplementary Table 1).
3.2. Glycemic control
Fig. 1 shows the changes in glycemic variables during the 24-
week treatment period. GA (%) decreased significantly from
23.7 ± 2.9 at baseline to 20.3 ± 2.0 at week 24 in the saxagliptin
group (P < 0.0001) but remained unchanged in the control
group, with values of 23.6 ± 2.7 and 23.6 ± 3.1 at baseline and
week 24, respectively. The GA level decreased significantly
at each visit in the saxagliptin group compared with baseline
and the control group. Twenty-two patients in the saxagliptin
group had a GA level <20% at the end of treatment. HbA1c and
PPG also decreased significantly in the saxagliptin group com-
pared with baseline levels and compared with corresponding
levels in the control group. Mean GA, HbA1c, and PPG all
decreased significantly in the saxagliptin group (3.4%,
0.6% [7 mmol/mol], and 38.3 mg/dL, respectively; all
P < 0.0001), but not in the control group (0%, 0.1%
[1 mmol/mol], and 3.7 mg/dL, respectively) (P < 0.0001,
P < 0.001, and P < 0.0001, respectively).3.3. Efficacy in subgroups of patients
The efficacy of saxagliptin was also examined in subgroups of
patients divided by the baseline variables age, BMI, and treat-
ment regimen. As shown in Table 2, the improvements in GA,
HbA1c, and PPG were comparable between subgroups of
patients divided by age (<70 vs. P70 years) and BMI (<23 vs.
P23 kg/m2).
When patients were divided into saxagliptin monotherapy
(n = 13) and combination therapy subgroups (saxagliptin plus
oral antidiabetic agents and/or insulin) (n = 28), we found no
significant differences in sex distribution, age, or BMI
between these subgroups. Notably, the reduction in GA was
significantly greater in the monotherapy subgroup than in
the combination therapy subgroup (4.2% vs. 3.0%,
P = 0.012) despite similar baseline values (24.5% vs. 23.3%).
The reduction in HbA1c was numerically greater in the
monotherapy subgroup (0.8% vs. 0.55%), albeit not signifi-
cantly (P = 0.053). By contrast, the reduction in PPG was com-
parable in both subgroups (41 vs. 37 mg/dL, P = 0.539).
We also calculated the reductions in GA, HbA1c, and PPG
in subgroups of saxagliptin-treated patients divided by the
median values of each variable at baseline (23.8% for GA,
6.6% for HbA1c, and 180 mg/dL for PPG) (Fig. 2). As shown in
this figure, the reductions in each variable from baseline to
week 24 were significantly greater in patients with values
exceeding the median at baseline.
Fig. 1 – GA (A), HbA1c (B), and PPG (C) at each visit. Results are presented as the mean ±SD. Black circles, saxagliptin group;
gray circles, control group. *P < 0.01 and ***P < 0.0001 vs. Week 0. †P < 0.01, ††P < 0.001, and †††P < 0.0001 vs. the control group.
GA, glycated albumin; HbA1c, hemoglobin A1c; PPG, postprandial plasma glucose.
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Table 3 shows the vital signs and laboratory variables at base-
line and at the end of the study in both groups. Of note, a sig-
nificant decrease in ERI was observed in the saxagliptin
group. In addition, saxagliptin was associated with a signifi-
cant decrease in triglyceride concentrations, which was prob-
ably secondary to its glucose-lowering effects.
3.5. Safety
None of the patients exhibited significant AEs such as symp-
tomatic hypoglycemia or liver dysfunction. Saxagliptin was
well tolerated, and it was not interrupted in any of the
patients. Although one patient in the saxagliptin group was
admitted to hospital because of pneumonia, this was not
related to saxagliptin treatment.
4. Discussion
Key findings of this study are that saxagliptin significantly
improved glycemic control in terms of GA, HbA1c, and PPG
when added to prior therapy compared with continuing prior
therapy in Japanese patients with type 2 diabetes on
hemodialysis. Furthermore, saxagliptin was well tolerated
and did not cause marked changes in vital signs or laboratory
variables.Earlier Japanese studies showed that other classes of
drugs, including a-glucosidase inhibitors (e.g., voglibose) and
glinides (e.g., mitiglinide), improved glycemic control and
were associated with low risks of hypoglycemia in hemodial-
ysis patients [3,4]. However, the current KDOQI recommenda-
tions suggest that the a-glucosidase inhibitors acarbose and
miglitol should be avoided in patients with glomerular filtra-
tion rates (GFR) <30 and <25 mL/min/1.73 m2, respectively,
and that the glinides repaglinide and nateglinide should be
used conservatively in patients with a GFR of <30 mL/
min/1.73 m2 [6]. Current KDOQI guidelines also mention the
need to avoid metformin and some sulfonylureas, and state
that the doses of DPP-4 inhibitors may need to be reduced.
In addition, the guidelines highlight the need to administer
saxagliptin at a lower dose (2.5 mg/day) in patients with a
GFR of 650 mL/min/1.73 m2 [6]. However, these recommenda-
tions were essentially based on Western studies and for
patients with stages 3–5 CKD, not necessarily those with
end-stage kidney disease or on dialysis. In addition, further
evidence of the efficacy of these drugs in Japanese patients
was needed.
Several DPP-4 inhibitors have been approved in Japan, and
prior studies have examined the efficacy and safety of aloglip-
tin, teneligliptin, and vildagliptin in Japanese hemodialysis
patients [7–9]. These studies showed significant improve-
ments in glycemic control without an increased risk of
hypoglycemia.
Table 2 – Subgroup analysis in the saxagliptin group.
Age (years) BMI (kg/m2) Treatment regimena
<70 P70 P value <23 P23 P value Monotherapy Combination P value
N 21 20 21 20 13 28
Males 14 (66.7) 13 (65.0) 0.453 12 (57.1) 15 (75.0) 0.238 10 (76.9) 17 (60.7) 0.320
Age (years) 60.6 ± 7.0 75.2 ± 3.9 <0.0001 64.4 ± 8.4 69.4 ± 10.0 0.086 66.6 ± 11.3 67.1 ± 8.1 0.846
BMI (kg/m2) 21.6 ± 3.8 23.8 ± 3.3 0.053 20.3 ± 2.1 26.1 ± 2.1 <0.0001 22.0 ± 1.9 23.5 ± 4.0 0.093
GA (%)
Baseline 24.5 ± 2.7 23.0 ± 3.1 0.114 24.5 ± 3.5 22.8 ± 1.9 0.056 24.5 ± 3.9 23.3 ± 2.3 0.217
Changeb 3.6 ± 2.1 3.2 ± 1.4 0.484 3.3 ± 2.0 3.5 ± 1.6 0.792 4.2 ± 1.8 3.0 ± 1.6 0.012
HbA1c (% [mmol/mol])
Baseline 6.5 ± 0.7 (48 ± 7.7) 6.5 ± 0.8 (48 ± 8.7) 0.918 6.5 ± 0.7 (48 ± 7.7) 6.5 ± 0.9 (48 ± 9.8) 0.764 6.6 ± 0.8 (49 ± 8.7) 6.4 ± 0.7
(46 ± 7.7)
0.575
Changeb 0.66 ± 0.41 (7.2 ± 4.5) 0.61 ± 0.48 (6.7 ± 5.2) 0.709 0.65 ± 0.50 (7.1 ± 5.5) 0.62 ± 0.38 (6.8 ± 4.2) 0.870 0.80 ± 0.58 (8.7 ± 6.3) 0.55 ± 0.34
(6.0 ± 3.7)
0.053
PPG (mg/dL)
Baseline 178 ± 29 195 ± 38 0.105 191 ± 32 181 ± 37 0.341 183 ± 29 187 ± 37 0.671
Changeb 40 ± 23 36 ± 23 0.566 41 ± 23 36 ± 23 0.456 41 ± 29 37 ± 24 0.539
BMI, body mass index; GA, glycated albumin; HbA1c, hemoglobin A1c; PPG, postprandial plasma glucose.
Values are shown as the n (%) or mean ± standard deviation.
a Saxagliptin was administered as monotherapy or in combination with oral antidiabetic agents and/or insulin.
b Change from baseline to week 24.
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Table 3 – Changes in vital signs and laboratory variables.
Variables Saxagliptin group Control group Between-group
P values
Baseline Endpoint P valuea Baseline Endpoint P valuea Baseline Endpoint
SBP (mmHg) 147 ± 12 146 ± 12 0.073 147 ± 12 148 ± 14 0.101 0.936 0.506
DBP (mmHg) 76 ± 9 76 ± 10 0.057 77 ± 13 77 ± 13 0.351 0.829 0.583
Heart rate (bpm) 77 ± 10 77 ± 10 0.937 77 ± 8 77 ± 8 0.509 0.971 0.925
Hemoglobin (g/dL) 11.0 ± 0.6 11.0 ± 0.7 0.392 11.0 ± 0.7 10.9 ± 0.7 0.381 0.923 0.332
ESA dose (U/week) 5902 ± 2421 4768 ± 2466 <0.0001 5926 ± 2639 5963 ± 2665 0.33 0.965 0.038
ERI 9.49 ± 4.42 7.77 ± 4.63 0.0008 9.73 ± 5.67 10.02 ± 5.15 0.847 0.829 0.041
Total protein (g/dL) 6.6 ± 0.3 6.6 ± 0.3 0.139 6.5 ± 0.5 6.5 ± 0.5 0.228 0.167 0.123
Serum albumin (g/dL) 3.6 ± 0.2 3.7 ± 0.3 0.141 3.7 ± 0.6 3.6 ± 0.3 0.157 0.477 0.184
AST (U/L) 15.3 ± 4.9 15.0 ± 4.1 0.327 15.0 ± 6.5 15.5 ± 6.9 0.47 0.802 0.699
ALT (U/L) 12.0 ± 6.3 11.8 ± 5.6 0.253 11.3 ± 6.6 12.2 ± 7.7 0.107 0.657 0.756
LDH (U/L) 183 ± 26 182 ± 25 0.224 180 ± 28 179 ± 29 0.649 0.692 0.649
ALP (U/L) 228 ± 40 230 ± 39 0.742 230 ± 61 223 ± 63 0.406 0.869 0.517
c-GTP (U/L) 21.4 ± 11.0 20.9 ± 10.3 0.168 21.2 ± 12.3 20.6 ± 11.2 0.374 0.932 0.983
Total cholesterol (mg/dL) 154 ± 32 151 ± 29 0.173 149 ± 22 148 ± 20 0.877 0.292 0.638
HDL-cholesterol (mg/dL) 44.7 ± 12.7 45.0 ± 12.7 0.781 42.4 ± 12.1 42.1 ± 12.0 0.755 0.39 0.286
Triglyceride (mg/dL) 98 (57–140) 86 (56–124) 0.0015 118 (77–144) 112 (84–167) 0.64 0.491 0.041
BMI (kg/m2) 22.7 ± 3.7 22.7 ± 3.6 0.813 22.9 ± 3.7 22.9 ± 3.8 0.969 0.837 0.848
Clinical dry weight (kg) 59.5 ± 13.1 59.6 ± 12.8 0.914 50.6 ± 13.4 60.6 ± 13.7 0.959 0.723 0.64
CTR (%) 49.0 ± 2.7 49.0 ± 2.6 0.222 49.9 ± 2.8 49.6 ± 3.0 0.761 0.136 0.355
Interdialytic weight gain (kg) 2.91 ± 0.99 2.77 ± 0.93 0.0015 2.93 ± 0.99 2.96 ± 1.05 0.145 0.904 0.573
SBP, systolic blood pressure; DBP, diastolic blood pressure; ESA, erythropoiesis stimulating agent; ERI, erythropoietin responsiveness index;
AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; ALP, alkaline phosphatase, c-GTP, c-glutamyl
transpeptidase; HDL, high-density lipoprotein; BMI, body mass index; CTR, cardiothoracic ratio.
Values are shown as the mean ± standard deviation or median (interquartile range).
a Within-group comparisons.
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Fig. 2 – Changes from baseline to the end of treatment in GA, HbA1c, and PPG in saxagliptin-treated patients according to
baseline GA (A), HbA1c (B), and PPG (C). Results are presented as themean ± standard deviation. GA, glycated albumin; HbA1c,
hemoglobin A1c; PPG, postprandial plasma glucose.
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and safety of saxagliptin in the hemodialysis setting, and
hence determine whether saxagliptin had similar properties
to alogliptin, teneligliptin and vildagliptin. Of note, we foundthat saxagliptin achieved significant reductions in the glyce-
mic variables GA, HbA1c, and PPG compared with the control
group. Moreover, saxagliptin was associated with a significant
reduction in triglyceride concentrations, which was probably
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triglyceride concentrations was also reported in the vildaglip-
tin study [8] but not in other studies.
Nowicki et al. examined the efficacy and safety of saxa-
gliptin in a heterogeneous cohort of patients with renal
impairment (moderate, severe, or end-stage kidney disease
on dialysis) in a phase III trial [14]. However, only 19 and 20
hemodialysis patients were randomized to saxagliptin and
placebo, respectively, of which 10 and 13 completed 12 weeks
of treatment and 6 and 9 completed 52 weeks of treatment.
Furthermore, they assessed glycemic control in terms of
HbA1c, not GA. For these reasons, additional studies were
necessary to provide better understanding of the efficacy
and safety of saxagliptin in hemodialysis patients. Mean-
while, Nakamura et al. reported that DPP4 inhibitors
decreased HbA1c and GA levels by 0.3%–1.3% and 1.7%–4.9%,
respectively, in hemodialysis patients [15]. However, that
report only included one saxagliptin study, the study by Now-
icki et al. [14]. The effects of saxagliptin on GA have not been
reported to date. Therefore, the present study was the first to
evaluate the efficacy of saxagliptin in terms of the changes in
both HbA1c and GA in a clearly defined cohort of hemodialy-
sis patients.
The present study also showed that saxagliptin was effec-
tive in subgroups of patients divided by baseline characteris-
tics, combination therapies, and baseline glycemic status.
Intriguingly, however, the efficacy of saxagliptin in terms of
the reduction in GAwas significantly greater in patients trea-
ted with saxagliptin as monotherapy than in patients treated
with saxagliptin in combination with other antidiabetic
drugs.
In this study, 28.0% of patients were on dietary therapy
alone and 21.9% were prescribed insulin with or without oral
antidiabetic agents. In previous studies, dietary therapy alone
and insulin were prescribed to 30% and 0% of patients,
respectively [8], to 50% and 0%, respectively [7], and to 40%
and 26.6%, respectively [9]. The proportions of patients on
dietary therapy alone may be explained by the fact that at
some centers, glycemic control of hemodialysis patients is
only assessed in terms of HbA1c, and antidiabetic agents
are not routinely prescribed to patients whose HbA1c is
<7.0%. Renal anemia, ESAs, and blood loss during hemodialy-
sis may lower HbA1c without lowering GA. Therefore, the pro-
portion of patients prescribed dietary therapy alone was
perhaps higher than might be expected in our study and in
these earlier studies, and more patients might be prescribed
antidiabetic therapies if glycemic control is assessed in terms
of GA instead of HbA1c.
Based on the laboratory variables and AEs observed in this
study, saxagliptin had no apparent safety concerns. In the
present study, 21.9% of patients were prescribed insulin with
or without oral antidiabetic agents, and 28.0% were pre-
scribed dietary therapy alone. Furthermore, sulfonylureas
are contraindicated in hemodialysis patients in Japan. It is
possible that the low use of insulin and the prohibited use
of sulfonylureas contributed to the low rate of adverse events
(especially hypoglycemia) in the present study, relative to that
in patients with moderate–severe renal impairment [14,16].
Intriguingly, however, there were reductions in the ESA dose,
ERI, and interdialytic weight gain in the saxagliptin grouprelative to the control group in our study. A small reduction
in interdialytic weight gain was also observed with vildaglip-
tin [8]. To our knowledge, this is the first report to show that a
DPP-4 inhibitor was associated with a reduction in ERI. It has
been reported that DPP-4 inhibitors have anti-inflammatory
effects and improve bone marrow function [17,18], which
may have contributed to the reductions in ERI and ESA dose
in the saxagliptin group observed in the present study. The
reduction in ERI is likely to be clinically relevant because it
may allow for lower doses of ESAs over the long term, thus
reducing exposure and treatment costs, and increasing cost-
effectiveness while maintaining target hemoglobin levels in
hemodialysis patients. However, these possibilities will need
to be addressed in future studies.
Unlike other DPP-4 inhibitors, saxagliptin is rapidly
excreted via hepatic and renal pathways. Approximately
25% of the dose undergoes renal excretion and approximately
22% is excreted in feces [19]. Consequently, renal impairment
increases the total bioavailability of saxagliptin with
increases in the area under the concentration–time curves
of 16%, 41%, and 108% in mild, moderate, and severe renal
impairment, respectively, compared with normal renal func-
tion [20]. Therefore, the dose of saxagliptin should be adjusted
based on the patient’s kidney function. By contrast, linagliptin
shows much lower renal elimination so dose adjustments are
unnecessary in patients with renal impairment. Although the
renal elimination profile of linagliptin suggests that it will be
an ideal agent for patients on dialysis, a randomized con-
trolled trial has not yet been conducted in this population
[21].
There are some limitations to this study. In particular, it
was conducted at just four centers, so might not reflect the
clinical management of hemodialysis patients throughout
Japan. In addition, the results may not be generalizable to
non-Japanese patients. Because this trial did not have a
double-blind design, the absence of masking may have intro-
duced a bias. Finally, the study was not adequately powered
for the subgroup analyses, so larger studies may be required
to confirm the efficacy of saxagliptin in these subgroups.
In conclusion, the present study showed that saxagliptin
at a dose of 2.5 mg/day was effective and well tolerated when
used as monotherapy or in combination with other antidia-
betic drugs in Japanese hemodialysis patients with type 2 dia-
betes. Longer-term studies are warranted to confirm the long-
term efficacy and safety of saxagliptin in these patients.Disclosure
MA has received honoraria from Kyowa Hakko Kirin Co. Ltd.
The other authors have no conflict of interest to declare.Authors’ contributions
Study concept and design: MA, TH; data acquisition: MA, TH,
MM, MO, RT, CN, HT, FK, HT; data analysis/interpretation: MA,
TH; statistical analysis: MA; supervision or mentorship: KO.
All authors contributed important intellectual content during
manuscript drafting or revision, and accept accountability for
the overall work, and ensured that questions pertaining to the
252 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 1 6 ( 2 0 1 6 ) 2 4 4 –2 5 2accuracy or integrity of the work were appropriately investi-
gated and resolved. MA takes responsibility that this study
is reported honestly, accurately, and transparently; that no
important aspects of the study have been omitted; and that
any discrepancies from the study were explained.
Acknowledgments
Publication of this report was financially supported by a grant
from Kyowa Hakko Kirin Co. Ltd. (No financial support was
received for implementation of this study.) Medical writing
support was provided by Dr. Nicholas D. Smith (Edanz Group
Ltd.) and Elsevier/ELMCOMTM. Kyowa Hakko Kirin Co. Ltd. was
not involved in the study design; in the collection, analysis
and interpretation of data; in the writing of the report; or in
the decision to submit the article for publication.
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.diabres.
2016.04.034.R E F E R E N C E S[1] Abe M, Okada K, Soma M. Antidiabetic agents in patients
with chronic kidney disease and end-stage renal disease on
dialysis: metabolism and clinical practice. Curr Drug Metab
2011;12:57–69.
[2] Abe M, Kalantar-Zadeh K. Haemodialysis-induced
hypoglycaemia and glycaemic disarrays. Nat Rev Nephrol
2015;11:302–13.
[3] Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K.
Efficacy and safety of mitiglinide in diabetic patients on
maintenance hemodialysis. Endocr J 2010;57:579–86.
[4] Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K.
Combination therapy with mitiglinide and voglibose
improves glycemic control in type 2 diabetic patients on
hemodialysis. Expert Opin Pharmacother 2010;11:169–76.
[5] Kidney Disease Outcomes Quality Initiative ((KDOQI)).
Clinical practice guidelines and clinical practice
recommendations for diabetes and chronic kidney disease.
Am J Kidney Dis 2007;49:S62–73.
[6] KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012
update. Am J Kidney Dis 2012;60:850–86.
[7] Fujii Y, Abe M, Higuchi T, Mizuno M, Suzuki H, Matsumoto S,
et al. The dipeptidyl peptidase-4 inhibitor alogliptin improves
glycemic control in type 2 diabetic patients undergoing
hemodialysis. Expert Opin Pharmacother 2013;14:259–67.[8] Ito M, Abe M, Okada K, Sasaki H, Maruyama N, Tsuchida M,
et al. The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin
improves glycemic control in type 2 diabetic patients
undergoing hemodialysis. Endocr J 2011;58:979–87.
[9] Otsuki H, Kosaka T, Nakamura K, Shimomura F, Kuwahara Y,
Tsukamoto T. Safety and efficacy of teneligliptin: a novel
DPP-4 inhibitor for hemodialysis patients with type 2
diabetes. Int Urol Nephrol 2014;46:427–32.
[10] Inoue K, Goto A, Kishimoto M, Tsujimoto T, Yamamoto-
Honda R, Noto H, et al. Possible discrepancy of HbA1c values
and its assessment among patients with chronic renal
failure, hemodialysis and other diseases. Clin Exp Nephrol
2015;19:1179–83.
[11] Williams ME, Mittman N, Ma L, Brennan JI, Mooney A,
Johnson CD, et al. The Glycemic Indices in Dialysis
Evaluation (GIDE) study: comparative measures of glycemic
control in diabetic dialysis patients. Hemodial Int
2015;19:562–71.
[12] Nakao T, Inaba M, Abe M, Kaizu K, Shima K, Babazono T, et al.
Best practice for diabetic patients on hemodialysis 2012. Ther
Apher Dial 2015;19(Suppl. 1):40–66.
[13] Higuchi T, AbeM, Yamazaki T, Okawa E, Ando H, Hotta S, et al.
Levocarnitine improves cardiac function in hemodialysis
patients with left ventricular hypertrophy: a randomized
controlled trial. Am J Kidney Dis 2015;67:260–70.
[14] Nowicki M, Rychlik I, Haller H, Warren M, Suchower L, Gause-
Nilsson I, et al. Long-term treatment with the dipeptidyl
peptidase-4 inhibitor saxagliptin in patients with type 2
diabetes mellitus and renal impairment: a randomised
controlled 52-week efficacy and safety study. Int J Clin Pract
2011;65:1230–9.
[15] Nakamura Y, Hasegawa H, Tsuji M, Udaka Y, Mihara M,
Shimizu T, et al. Diabetes therapies in hemodialysis patients:
dipeptidase-4 inhibitors. World J Diabetes 2015;6:840–9.
[16] Udell JA, Bhatt DL, Braunwald E, Cavender MA, Mosenzon O,
Steg PG, et al. Saxagliptin and cardiovascular outcomes in
patients with type 2 diabetes and moderate or severe renal
impairment: observations from the SAVOR-TIMI 53 trial.
Diabetes Care 2015;38:696–705.
[17] Avogaro A, Fadini GP. The effects of dipeptidyl peptidase-4
inhibition on microvascular diabetes complications. Diabetes
Care 2014;37:2884–94.
[18] Satoh-Asahara N, Sasaki Y, Wada H, Tochiya M, Iguchi A,
Nakagawachi R, et al. A dipeptidyl peptidase-4 inhibitor,
sitagliptin, exerts anti-inflammatory effects in type 2 diabetic
patients. Metabolism 2013;62:347–51.
[19] Anderson R, Hayes J, Stephens JW. Pharmacokinetic,
pharmacodynamic and clinical evaluation of saxagliptin in
type 2 diabetes. Expert Opin Drug Metab Toxicol 2016:1–7.
[20] Flynn C, Bakris GL. Noninsulin glucose-lowering agents for
the treatment of patients on dialysis. Nat Rev Nephrol
2013;9:147–53.
[21] Abe M, Okada K. DPP-4 inhibitors in diabetic patients with
chronic kidney disease and end-stage kidney disease on
dialysis in clinical practice. Contrib Nephrol 2015;185:98–115.
